1. Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension
- Author
-
Mark S. Dooner, Thomas Walsh, Margaret R. MacLean, Athena Poppas, Jason M. Aliotta, Elizabeth O. Harrington, Melissa Allahua, Corey E. Ventetuolo, Grayson L. Baird, Christopher J Mullin, Alexander S. Brodsky, James R. Klinger, Mandy Pereira, Nina Denver, Mary Whittenhall, Ruth Andrew, and Ghada Bourjeily
- Subjects
Pulmonary and Respiratory Medicine ,RM ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,media_common.quotation_subject ,Physiology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Dehydroepiandrosterone sulfate ,medicine ,Humans ,030212 general & internal medicine ,Gonadal Steroid Hormones ,Menstrual cycle ,Menstrual Cycle ,media_common ,Original Research ,Pulmonary Arterial Hypertension ,business.industry ,medicine.disease ,Pulmonary hypertension ,030228 respiratory system ,chemistry ,Observational study ,Female ,business ,Hormone - Abstract
Rationale: Sex hormones play a role in pulmonary arterial hypertension (PAH), but the menstrual cycle has never been studied. Objectives: We conducted a prospective observational study of eight women with stable PAH and 20 healthy controls over one cycle. Methods: Participants completed four study visits 1 week apart starting on the first day of menstruation. Relationships between sex hormones, hormone metabolites, and extracellular vesicle microRNA (miRNA) expression and clinical markers were compared with generalized linear mixed modeling. Results: Women with PAH had higher but less variable estradiol (E2) levels (P
- Published
- 2021